This website requires a modern Browser to work. If you see this message, please try either Chrome or Firefox.
If you see this message for more than a few seconds you are probably using an older browser.
This website uses javascript and works best on Chrome, Firefox, Safari, and Edge.
image
Opening
a new frontier
in pharmacology
Opening a new frontier
in pharmacology
Opening
a new frontier
in pharmacology
A pipeline of breakthrough
pharmacological inhibitors
Signaling Specific inhibitors
of the CB1 (CB1-SSi)
Targeting diseases while protecting physiology
AEF0117 for cannabis-related disorders
AEF0217 for the treatment of cognitive deficits
Aelis Farma’s Mission
Conjugate the scientific breakthrough of CB1-SSi with innovative drug development to provide new specific and safe treatments for CNS diseases with unmet medical needs.
Pier Vincenzo Piazza, CEO
Latest News
The European Commission grants €6 million to the ICOD project for the development of AEF0217 (AELIS FARMA) to treat cognitive deficits in Down syndrome
April 2021
+
Anders Gersel Pedersen appointed Chairman of the Board of Directors of AELIS FARMA
November 2020
+